Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.
about
Treatment of heparin-induced thrombocytopenia.Pharmacotherapy of heparin- induced thrombocytopenia.Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing.Treatment of heparin-induced thrombocytopenia in cardiovascular patients.Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.Fondaparinux as a treatment option for heparin-induced thrombocytopenia.Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.Direct thrombin inhibitors for anticoagulation.Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.The safety of fondaparinux for the prevention and treatment of venous thromboembolism.Short- and long-acting synthetic pentasaccharides as antithrombotic agents.Clinical efficacy and safety of fondaparinux in the prevention and treatment of venous and arterial thrombosis.Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications.
P2860
Q31042575-3763466C-FB56-488A-AF46-D8ABF1E34DE9Q33348283-DF32CD21-088D-4EBF-A1F4-0C51EEAEA152Q33362184-0C993F03-9001-4B7F-9F3A-C198222CB98BQ33370137-6E1EC389-F63A-44B3-88E6-94390DABF655Q33370696-E85E14C3-277A-4A02-BAB0-14D895A3A1ABQ33375448-ACA168FB-8DCB-40AF-8F72-FC802E67E908Q33386145-D61FC534-7A9F-486A-B8B6-D5E3A246ECBFQ34116036-455D6CD9-747D-4DF8-81C4-00BEB1789883Q35160253-C108C8BC-1AFC-4A29-BC2A-A8BEEF9B6721Q35562634-EB675490-D8E7-433B-B5C0-04D8E34C26F9Q35638059-47D3E897-D4EE-4B3F-B410-868844675DCDQ35866092-B044A70E-7CDE-4B15-8490-E37DB3F8BB5CQ36191034-70FDDDDB-6E37-4193-BBA1-9DB38C744D8DQ36196467-C1FB13BE-F322-490B-9792-C2E61795E96DQ37608455-EE254290-BA12-4CAD-B8B2-C32E46D1476CQ38303999-C17A572C-2346-4A50-A4EA-62F802AC5372
P2860
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Synthetic pentasaccharides do ...... -platelet factor 4 antibodies.
@ast
Synthetic pentasaccharides do ...... -platelet factor 4 antibodies.
@en
Synthetic pentasaccharides do ...... -platelet factor 4 antibodies.
@nl
type
label
Synthetic pentasaccharides do ...... -platelet factor 4 antibodies.
@ast
Synthetic pentasaccharides do ...... -platelet factor 4 antibodies.
@en
Synthetic pentasaccharides do ...... -platelet factor 4 antibodies.
@nl
prefLabel
Synthetic pentasaccharides do ...... -platelet factor 4 antibodies.
@ast
Synthetic pentasaccharides do ...... -platelet factor 4 antibodies.
@en
Synthetic pentasaccharides do ...... -platelet factor 4 antibodies.
@nl
P2093
P2860
P1476
Synthetic pentasaccharides do ...... -platelet factor 4 antibodies.
@en
P2093
Herbert JM
Hoppensteadt DA
Messmore HL
Walenga JM
P2860
P304
P356
10.1177/107602969900500410
P577
1999-10-01T00:00:00Z